Current ALS Research Studies at the University of Kentucky

Clinical Drug Studies:
• The CENTAUR Study sponsored by Amylyx Pharmaceuticals and Massachusetts General Hospital – In this Phase II study, we are looking at two drugs that have previously been tested in individuals with ALS and showed some promise. The goal of this study is to see whether the combined effect of both drugs can slow down the progression of ALS. It is administered orally. We are currently ENROLLING for this study.
• The PENNANT Study sponsored by Mallinckrodt Pharmaceuticals – In this Phase II study, we are asking individuals with ALS to administer a corticosteroid subcutaneously (injection under the skin). This is another study where the goal is to see whether or not this investigational drug can help slow down ALS progression. We are currently ENROLLING for this study.
• TRANSLATE – Only open to individuals who have a known mutation in the FUS gene and ALS and/or their family members. In this study, we are looking to see whether or not the administration of an intramuscular injection of betamethasone can help reduce oxidative stress. We are currently ENROLLING for this study.
• REFALS sponsored by Orion Pharmaceuticals – University of Kentucky has recently been selected as site for this Phase III study with potential start date in late 2018.
Investigator-Initiated Studies:
• DNA Banking and FUS Gene Research – Patients and their family members who are identified to be likely to have a specific genetic mutation may offer blood samples and/or skin biopsy samples for Dr. Kasarskis and his research team to study to learn more about the way that genetic mutation causes disease. The ultimate goal would be to determine a way to turn off the genetic mutation that causes disease; and/or to prevent the development of the disease when someone gets the genetic mutation.
• Sialorrhea (drooling) Study with Radiation Medicine – Dr. Kasarskis and his research team are evaluating the effectiveness of Electron Beam Radiation in decreasing saliva production to improve the troublesome symptom of Sialorrhea, or excessive Saliva, in patients with ALS and other debilitating neurological disorders.
• Residential Survey of ALS Patients living in KY, OH, WV, TN, and IN – Dr. Kasarskis and his research team are looking for environmental factors that are associated with an increased risk for developing ALS. Willing participants are asked to complete a survey that includes their lifelong residential and occupational history (every place they have lived, and their occupation while they lived there.) This study is open to all ALS patients
• AWARE Quality of Life Study – Dr. Debra Suiter, PhD, Speech Language Pathologist at UK ALS Center, is conducting a clinical observational study to examine the quality of life of patients with swallowing problems related to ALS and their caregivers.
Please feel free to call at any time regarding ALS Clinical Trials!
CONTACTS:
University of Kentucky ALS Center
Kentucky Clinic – Kentucky Neuroscience Institute
740 S. Limestone Street, J-401
Lexington, Ky 40536-0284
Edward J. Kasarskis, MD, PhD
Neurologist / Principal Investigator
E-mail:edward.kasarskis@uky.edu
Meha Joshi, BA
Clinical Research Coordinator
Office Phone: (859) 218-5046
Office Fax: (859) 257-8990
E-mail:majo235@uky.edu
Meghann Bruno, RN, BSN
Clinical Research Nurse
Office Phone: (859) 218-5064
Office Fax: (859) 257-8990
E-mail:meghann.bruno@uky.edu
 
No